The CEO of Kite Pharma plans to initiate early conversations with insurers, even before the launch of a clinical trial of their experimental drug, to ensure smooth sailing once the product is approved and launched.
Kite Pharma Inc plans to open conversations with insurers this year to lay the groundwork for an experimental cancer treatment that could cost hundreds of thousands of dollars if it works and is approved by regulators, top executives said this week.
The possible treatment has yet to start a broad clinical trial, but the urgency comes as biotech and pharma companies consider how to navigate pushback by health insurers against GileadSciences
Inc on the price of its hepatitis C treatment.
Read the full report on Reuters: http://reut.rs/1ukdYtz